Cardiff Oncology Inc

NASDAQ:CRDF  
5.23
-0.23 (-4.21%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)210.63M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.05 Million
Adjusted EPS-$0.17
See more estimates
10-Day MA$5.45
50-Day MA$6.10
200-Day MA$7.47
See more pivots

Cardiff Oncology Inc Stock, NASDAQ:CRDF

11055 Flintkote Avenue, Suite B, San Diego, California 92121
United States of America
Phone: +1.858.952.7570
Number of Employees: 12

Description

Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. The firm's clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.